Médecine

Paramédical

Autres domaines


S'abonner

The dermal-based borderline melanocytic tumor: A categorical approach - 24/04/13

Doi : 10.1016/j.jaad.2009.06.042 
Cynthia M. Magro, MD a, , A. Neil Crowson, MD c, Martin C. Mihm, MD d, Kapil Gupta, MD e, Michael J. Walker, MD f, Garron Solomon, MD b
a Weill Medical College of Cornell University, New York, New York 
b Strata Pathology Services Incorporated, Lexington, Massachusetts 
c Regional Medical Laboratory, St. John’s Medical Center, University of Oklahoma, Tulsa, Oklahoma 
d Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 
e Dermatology Group of the Carolinas, Concord, NC 
f The Ohio State University, Columbus, Ohio 

Reprint requests: Cynthia M. Magro, MD, Department of Pathology, Weill Medical College of Cornell University, 1300 York Ave, F-309, New York, NY 10021.

Abstract

Background

The borderline melanocytic tumor (BMT) is a morphologically and biologically indeterminate melanocytic proliferation manifesting worrisome architectural features and cytologic atypia exceeding that encountered in melanocytic nevi yet insufficient to warrant designation as melanoma. The criteria that define the BMT are not well defined nor is the concept widely recognized.

Objective

The purpose of this study is to provide a practical framework for the approach to the dermal BMT.

Methods

Thirty-two patients with BMTs extending into the reticular dermis and at a depth of 0.75 mm or more underwent local excision and sentinel lymph node biopsy between 2000 and 2006. Four categories of BMT were recognized: (1) nevoid BMT (BNM); (2) the atypical Spitz tumor (AST); (3) pigmented epithelioid melanocytoma (PEM); and (4) BMT arising in a deep penetrating nevus (B-DPN).

Results

Four patients were in the BNM category (male/female ratio [M:F] = 1:3; mean age = 27 years, range = 15-36), 14 in the AST category (M:F = 7:7; mean age = 20.9, range = 3-58), 7 in the PEM category (M:F = 4:3; mean age = 23.5, range = 3-39), and 7 in the B-DPN category (M:F = 5:2; mean age = 22.3, range = 14-36). The percentages of patients with positive sentinel nodes in each category were 25% (1/4), 35% (5/14), 14% (1/7), and 57% (4/7), respectively. The average time of follow-up was approximately 4.2 years. One patient, a 36-year-old man, died of disease, while the others are alive and well. In the one death attributable to widespread metastatic disease, the lesion was initially interpreted as a deep penetrating nevus; however, retrospective review revealed features compatible with a B-DPN; the review was prompted by a recurrence that was morphologically compatible with a Clark level V malignant melanoma, reflecting clinical and morphologic progression.

Limitations

The mean follow-up was less than 5 years. Molecular studies to further explore the biologic commonality with melanoma were not performed.

Conclusion

The dermal variant of BMT is a tumor of younger adults and children that can be associated with lymph node disease and a potential for morphologic and biologic progression when inadequately treated.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : AST, B-DPN, BMT, BNM, CGH, FISH, mirRNA, PEM


Plan


 Funding sources: None.
 Conflicts of interest: None declared.


© 2009  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 62 - N° 3

P. 469-479 - mars 2010 Retour au numéro
Article précédent Article précédent
  • Epidermotropic Merkel cell carcinoma: A case series with histopathologic examination
  • Mark D’Agostino, Christina Cinelli, Robert Willard, Jeffrey Hofmann, Nathaniel Jellinek, Leslie Robinson-Bostom
| Article suivant Article suivant
  • X-linked ichthyosis: An oculocutaneous genodermatosis
  • Neil F. Fernandes, Camila K. Janniger, Robert A. Schwartz

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.